American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Elotuzumab plus Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory MM: ELOQUENT-2 Trial Update

ASH 2015 – Multiple Myeloma

In a phase 3 study, researchers assessed the safety and efficacy of elotuzumab plus lenalidomide/dexamethasone, the first immunostimulatory monoclonal antibody for the treatment of relapsed/refractory multiple myeloma. Here, they report 3-year follow-up data. Read More ›

Total Therapy GIMEMA LAL 1509 Protocol for De Novo Adult Ph+ ALL Patients: Updated Results and Genetic-Based Prognostic Stratification

ASH 2015 – Leukemia

ASH 2015 – Multiple Myeloma

Using a combined analysis of 2 DARA clinical studies, researchers assessed the overall response rates and clinical activity of a 16-mg/kg infusion for the treatment of relapsed and refractory multiple myeloma in heavily treated patients. Read More ›

Frontline Hyper-CVAD plus Ofatumumab for Adult Patients with CD-20–Positive ALL

ASH 2015 – Leukemia

ASH 2015 – Multiple Myeloma

Researchers reported on a study that assessed the clinical utility of minimal residual disease (MRD) monitoring in elderly patients with multiple myeloma (MM) included in the PETHEMA/GEM2010MAS65 trial. Read More ›

Carfilzomib/Dexamethasone versus Bortezomib/Dexamethasone in Relapsed MM: Subgroup Analysis Based on Cytogenetic Risk Status of the ENDEAVOR Study

ASH 2015 – Multiple Myeloma

The ENDEAVOR study demonstrated that carfilzomib plus dexamethasone showed a significant improvement in median progression-free survival compared with bortezomib plus dexamethasone. This update examines outcomes in patients in high-risk cytogenetic subgroups. Read More ›

Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CHAMPION-1)

ASH 2015 – Multiple Myeloma

ASH 2015 – Leukemia

American Society of Hematology (ASH)

Page 33 of 44